Skip to main content
Erschienen in: Skeletal Radiology 7/2016

28.03.2016 | Scientific Article

Symplastic/pseudoanaplastic giant cell tumor of the bone

verfasst von: Judy Sarungbam, Narasimhan Agaram, Sinchun Hwang, Chao Lu, Lu Wang, John Healey, Meera Hameed

Erschienen in: Skeletal Radiology | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Objective

Giant cell tumor of bone (GCTB) is a locally aggressive primary bone tumor. Its malignant counterpart is quite rare. Rarely, a conventional GCTB shows marked nuclear atypia, referred to as symplastic/pseudoanaplastic change, which can mimic sarcomatous transformation. Recently, somatic driver mutations of histone H3.3 exclusively in H3F3A have been described in GCTB. We report a series of 9 cases of GCTB with symplastic/pseudoanaplastic change, along with analysis of H3F3A variants.

Materials and methods

Nine cases of GCTB with symplastic change were identified. Clinico-radiological features, morphological features, and immunohistochemical stain for Ki-67 stain were reviewed. H3F3A variants were also analyzed using Sanger sequencing.

Results

Histologically, conventional giant cell tumor areas with scattered foci of markedly atypical cells were seen in all of the cases and all showed rare if any Ki-67 labeling. One patient had received denosumab treatment and another radiation therapy. Radiological features were characteristic of conventional GCTB. Mutation in H3F3A (p.Gly34Trp [G34W]) was found in 6 of the 7 cases. Clinical follow-up ranged from 6 to 208 months. Local recurrences were seen in 4 cases (44 %).

Conclusions

GCTB with symplastic/pseudoanaplastic change is an uncommon variant of conventional GCTB, which can mimic primary sarcoma or sarcomatous transformation. These tumors possess the same missense mutation in histone H3.3 as conventional GCTB.
Literatur
1.
Zurück zum Zitat Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the surveillance, epidemiology and end results program (1975–2004). Rare Tumors. 2009;1(2), e52.PubMedPubMedCentral Beebe-Dimmer JL, Cetin K, Fryzek JP, Schuetze SM, Schwartz K. The epidemiology of malignant giant cell tumors of bone: an analysis of data from the surveillance, epidemiology and end results program (1975–2004). Rare Tumors. 2009;1(2), e52.PubMedPubMedCentral
2.
Zurück zum Zitat Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 2002;117(2):210–6.CrossRefPubMed Roux S, Amazit L, Meduri G, Guiochon-Mantel A, Milgrom E, Mariette X. RANK (receptor activator of nuclear factor kappa B) and RANK ligand are expressed in giant cell tumors of bone. Am J Clin Pathol. 2002;117(2):210–6.CrossRefPubMed
3.
Zurück zum Zitat Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. 2003;97(10):2520–9.CrossRefPubMed Bertoni F, Bacchini P, Staals EL. Malignancy in giant cell tumor of bone. Cancer. 2003;97(10):2520–9.CrossRefPubMed
4.
Zurück zum Zitat Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969–78.CrossRefPubMed Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, Koehler G, et al. Giant cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin Oncol. 2008;134(9):969–78.CrossRefPubMed
5.
Zurück zum Zitat Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591–9.CrossRefPubMedPubMedCentral Klenke FM, Wenger DE, Inwards CY, Rose PS, Sim FH. Giant cell tumor of bone: risk factors for recurrence. Clin Orthop Relat Res. 2011;469(2):591–9.CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, et al. Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res. 2002;397:248–58.CrossRefPubMed Turcotte RE, Wunder JS, Isler MH, Bell RS, Schachar N, Masri BA, et al. Giant cell tumor of long bone: a Canadian sarcoma group study. Clin Orthop Relat Res. 2002;397:248–58.CrossRefPubMed
7.
Zurück zum Zitat Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479–82.CrossRefPubMed Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat Genet. 2013;45(12):1479–82.CrossRefPubMed
8.
9.
Zurück zum Zitat Layfield LJ, Bentley RC, Mirra JM. Pseudoanaplastic giant cell tumor of bone. Arch Pathol Lab Med. 1999;123(2):163–6.PubMed Layfield LJ, Bentley RC, Mirra JM. Pseudoanaplastic giant cell tumor of bone. Arch Pathol Lab Med. 1999;123(2):163–6.PubMed
10.
Zurück zum Zitat Dahl I, Hagmar B, Idvall I. Benign solitary neurilemmoma (Schwannoma). A correlative cytological and histological study of 28 cases. Acta Pathol Microbiol Scand A Pathol. 1984;92(2):91–101. Dahl I, Hagmar B, Idvall I. Benign solitary neurilemmoma (Schwannoma). A correlative cytological and histological study of 28 cases. Acta Pathol Microbiol Scand A Pathol. 1984;92(2):91–101.
11.
Zurück zum Zitat Lin BT, Weiss LM, Medeiros LJ. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol. 1997;21(12):1443–9.CrossRefPubMed Lin BT, Weiss LM, Medeiros LJ. Neurofibroma and cellular neurofibroma with atypia: a report of 14 tumors. Am J Surg Pathol. 1997;21(12):1443–9.CrossRefPubMed
12.
Zurück zum Zitat Siti-Aishah MA, Noriah O, Malini MN, Zainul-Rashid MR, Das S. Atypical (symplastic) leiomyoma of the uterus—a case report. Clin Ter. 2011;162(5):447–50.PubMed Siti-Aishah MA, Noriah O, Malini MN, Zainul-Rashid MR, Das S. Atypical (symplastic) leiomyoma of the uterus—a case report. Clin Ter. 2011;162(5):447–50.PubMed
13.
Zurück zum Zitat Bertoni F, Fernando Arias L, Alberghini M, Bacchini P. Fibrous dysplasia with degenerative atypia: a benign lesion potentially mistaken for sarcoma. Arch Pathol Lab Med. 2004;128(7):794–6.PubMed Bertoni F, Fernando Arias L, Alberghini M, Bacchini P. Fibrous dysplasia with degenerative atypia: a benign lesion potentially mistaken for sarcoma. Arch Pathol Lab Med. 2004;128(7):794–6.PubMed
14.
Zurück zum Zitat Bertoni F, Unni KK, McLeod RA, Dahlin DC. Osteosarcoma resembling osteoblastoma. Cancer. 1985;55(2):416–26.CrossRefPubMed Bertoni F, Unni KK, McLeod RA, Dahlin DC. Osteosarcoma resembling osteoblastoma. Cancer. 1985;55(2):416–26.CrossRefPubMed
15.
Zurück zum Zitat Cheung FM, Wu WC, Lam CK, Fu YK. Diagnostic criteria for pseudomalignant osteoblastoma. Histopathology. 1997;31(2):196–200.CrossRefPubMed Cheung FM, Wu WC, Lam CK, Fu YK. Diagnostic criteria for pseudomalignant osteoblastoma. Histopathology. 1997;31(2):196–200.CrossRefPubMed
16.
Zurück zum Zitat Craver RD, Heinrich S, Mirra J. Fibrous cortical defect with bizarre nuclear features. Ann Diagn Pathol. 1997;1(1):26–30.CrossRefPubMed Craver RD, Heinrich S, Mirra J. Fibrous cortical defect with bizarre nuclear features. Ann Diagn Pathol. 1997;1(1):26–30.CrossRefPubMed
17.
Zurück zum Zitat Desai SS, Jambhekar NA, Samanthray S, Merchant NH, Puri A, Agarwal M. Chondromyxoid fibromas: a study of 10 cases. J Surg Oncol. 2005;89(1):28–31.CrossRefPubMed Desai SS, Jambhekar NA, Samanthray S, Merchant NH, Puri A, Agarwal M. Chondromyxoid fibromas: a study of 10 cases. J Surg Oncol. 2005;89(1):28–31.CrossRefPubMed
18.
Zurück zum Zitat Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature. Cancer. 1979;44(4):1393–402.CrossRefPubMed Nascimento AG, Huvos AG, Marcove RC. Primary malignant giant cell tumor of bone: a study of eight cases and review of the literature. Cancer. 1979;44(4):1393–402.CrossRefPubMed
19.
Zurück zum Zitat Terasaki K, Mera Y, Uchimiya H, Katahira Y, Kanzaki T. Plexiform schwannoma. Clin Exp Dermatol. 2003;28(4):372–4.CrossRefPubMed Terasaki K, Mera Y, Uchimiya H, Katahira Y, Kanzaki T. Plexiform schwannoma. Clin Exp Dermatol. 2003;28(4):372–4.CrossRefPubMed
20.
Zurück zum Zitat Ismail FW, Shamsudin AM, Wan Z, Daud SM, Samarendra MS. Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone. J Exp Clin Cancer Res. 2010;29:25.CrossRefPubMedPubMedCentral Ismail FW, Shamsudin AM, Wan Z, Daud SM, Samarendra MS. Ki-67 immuno-histochemistry index in stage III giant cell tumor of the bone. J Exp Clin Cancer Res. 2010;29:25.CrossRefPubMedPubMedCentral
21.
Zurück zum Zitat Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol. 2016;40(1):72–80.CrossRefPubMed Wojcik J, Rosenberg AE, Bredella MA, Choy E, Hornicek FJ, Nielsen GP, et al. Denosumab-treated giant cell tumor of bone exhibits morphologic overlap with malignant giant cell tumor of bone. Am J Surg Pathol. 2016;40(1):72–80.CrossRefPubMed
22.
Zurück zum Zitat Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.CrossRefPubMed Thomas D, Henshaw R, Skubitz K, Chawla S, Staddon A, Blay JY, et al. Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study. Lancet Oncol. 2010;11(3):275–80.CrossRefPubMed
23.
Zurück zum Zitat Dahlin DC, Cupps RE, Johnson Jr EW. Giant-cell tumor: a study of 195 cases. Cancer. 1970;25(5):1061–70.CrossRefPubMed Dahlin DC, Cupps RE, Johnson Jr EW. Giant-cell tumor: a study of 195 cases. Cancer. 1970;25(5):1061–70.CrossRefPubMed
24.
Zurück zum Zitat Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64(5):755–61.PubMed Sung HW, Kuo DP, Shu WP, Chai YB, Liu CC, Li SM. Giant-cell tumor of bone: analysis of two hundred and eight cases in Chinese patients. J Bone Joint Surg Am. 1982;64(5):755–61.PubMed
25.
Zurück zum Zitat Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999;81(6):811–20.PubMed Blackley HR, Wunder JS, Davis AM, White LM, Kandel R, Bell RS. Treatment of giant-cell tumors of long bones with curettage and bone-grafting. J Bone Joint Surg Am. 1999;81(6):811–20.PubMed
26.
Zurück zum Zitat Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res. 2004;424:221–6.CrossRefPubMed Saiz P, Virkus W, Piasecki P, Templeton A, Shott S, Gitelis S. Results of giant cell tumor of bone treated with intralesional excision. Clin Orthop Relat Res. 2004;424:221–6.CrossRefPubMed
27.
Zurück zum Zitat Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1(2):113–23.CrossRef Presneau N, Baumhoer D, Behjati S, Pillay N, Tarpey P, Campbell PJ, et al. Diagnostic value of H3F3A mutations in giant cell tumour of bone compared to osteoclast-rich mimics. J Pathol Clin Res. 2015;1(2):113–23.CrossRef
28.
Zurück zum Zitat Cleven AH, Hocker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovee JV. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39(11):1576–83.CrossRefPubMed Cleven AH, Hocker S, Briaire-de Bruijn I, Szuhai K, Cleton-Jansen AM, Bovee JV. Mutation analysis of H3F3A and H3F3B as a diagnostic tool for giant cell tumor of bone and chondroblastoma. Am J Surg Pathol. 2015;39(11):1576–83.CrossRefPubMed
29.
Zurück zum Zitat Gomes CC, Diniz MG, Amaral FR, Antonini Guimaraes BV, Gomez RS. The highly prevalent H3F3A mutation in giant cell tumours of bone is not shared by sporadic central giant cell lesion of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(5):583–5.CrossRefPubMed Gomes CC, Diniz MG, Amaral FR, Antonini Guimaraes BV, Gomez RS. The highly prevalent H3F3A mutation in giant cell tumours of bone is not shared by sporadic central giant cell lesion of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol. 2014;118(5):583–5.CrossRefPubMed
30.
Zurück zum Zitat Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde I, Wu J, et al. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014;53(1):15–24.CrossRefPubMedPubMedCentral Joseph CG, Hwang H, Jiao Y, Wood LD, Kinde I, Wu J, et al. Exomic analysis of myxoid liposarcomas, synovial sarcomas, and osteosarcomas. Genes Chromosomes Cancer. 2014;53(1):15–24.CrossRefPubMedPubMedCentral
Metadaten
Titel
Symplastic/pseudoanaplastic giant cell tumor of the bone
verfasst von
Judy Sarungbam
Narasimhan Agaram
Sinchun Hwang
Chao Lu
Lu Wang
John Healey
Meera Hameed
Publikationsdatum
28.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Skeletal Radiology / Ausgabe 7/2016
Print ISSN: 0364-2348
Elektronische ISSN: 1432-2161
DOI
https://doi.org/10.1007/s00256-016-2373-z

Weitere Artikel der Ausgabe 7/2016

Skeletal Radiology 7/2016 Zur Ausgabe

Test Yourself: Question

Painful lateral foot swelling

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.